Hyzart

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hyzart

Property Description
Active Ingredients Losartan Potassium, Hydrochlorothiazide
Form Film-coated tablet (Oral)
Pharmacological Class Angiotensin II Receptor Blocker (ARB) and Thiazide Diuretic combination
General Purpose Management of high blood pressure (Hypertension)
Origin Synthetic small molecule compounds

Hyzart is a prescription-only medication defined as a Fixed-Dose Combination (FDC) product, designed for the management of high blood pressure, or Hypertension. It is an Antihypertensive Agent containing two separate synthetic active ingredients: Losartan Potassium and Hydrochlorothiazide. This FDC structure means both agents are combined into a single oral tablet for administration, a feature that supports consistency in complex treatment plans.


What Type of Medicine is Hyzart?

Hyzart represents a combination of two distinct pharmacological classes, a strategy clinically recognized for providing effective, multi-target blood pressure control.

Losartan Potassium acts as the ARB, and Hydrochlorothiazide acts as the diuretic component. Pairing these two agents is recognized as a standard strategy for achieving blood pressure targets in hypertensive patients. The use of the Losartan/Hydrochlorothiazide combination is well-established as a therapeutic option, forming the basis for multiple common brands, including Hyzaar, which utilize this identical formulation.


What Are the Active Ingredients and General Purpose?

The active ingredients in Hyzart are Losartan Potassium and Hydrochlorothiazide, whose primary role is to provide dual-action control over systemic blood pressure.

The Losartan component works to promote vasodilation by relaxing the blood vessels, while the Hydrochlorothiazide component induces controlled diuresis (fluid loss), thereby reducing the overall fluid volume circulating within the cardiovascular system. This combination is indicated to lower high blood pressure. By reducing this chronic, excessive pressure, the medication helps minimize strain on the heart and blood vessels, serving the general purpose of improving cardiovascular stability in adults with Hypertension.

Regulatory References

  1. NIH Antihypertensive Combination Review
  2. FDA DailyMed Monograph

What side effects are possible with Hyzart?

Possible Side Effects and Safety Information

The safety profile for Hyzart, the combination of Losartan and Hydrochlorothiazide, is officially documented by government regulatory bodies, detailing potential adverse reactions and constraints on use.

Official Adverse Reaction Classifications

Side effects are categorized by frequency and the body system affected, based on reported clinical data:

  • Common (ge 1/100 to < 1/10): Includes neurological effects like Dizziness and Headache, as well as general issues such as Upper Respiratory Infection and Nasal Congestion.
  • Uncommon (ge 1/1,000 to < 1/100): Adverse effects on the cardiovascular system (Palpitations) and gastrointestinal system (Nausea, Diarrhea) are officially listed in this category.
  • Rare (ge 1/10,000 to < 1/1,000): These include serious hypersensitivity reactions like Angioedema (swelling of the face, lips, or throat) and Hepatitis (liver inflammation).

Documented Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights several serious adverse reactions and limitations, which are formally designated as constraints on use:

  • Fetal Toxicity: Use is contraindicated during the second and third trimesters of pregnancy due to the risk of injury or death to the developing fetus.
  • Organ Impairment: The medicine is contraindicated in patients with an established history of Anuria (absence of urine formation) or Severe Hepatic Impairment.
  • Long-Term Exposure Risk: Cumulative, long-term use of the Hydrochlorothiazide component is formally associated with an increased risk of Non-Melanoma Skin Cancer.
  • Hypersensitivity: Safety constraints include a contraindication for individuals with a known allergy to sulfonamide-derived drugs, due to the Hydrochlorothiazide component.

Time-Related Safety Patterns

Official documents note that certain effects are time-dependent; for instance, Postural Hypotension (dizziness upon standing) is reported as being more likely to occur at the initiation of therapy, particularly in patients who are volume-depleted.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for the Losartan Potassium/Hydrochlorothiazide combination primarily by the exaggeration of its blood pressure-lowering and diuretic effects. Overdose may lead to severe physiological derangements, which necessitate immediate emergency action.

Documented Clinical Manifestations

Overdose presentations are defined by marked effects on the cardiovascular system and fluid balance:

  • Profound Hypotension: Excessively low blood pressure is the most likely and serious manifestation.
  • Cardiac Signs: Tachycardia (rapid heartbeat) and, less commonly, bradycardia (slow heartbeat) may occur.
  • Metabolic Effects: Signs of volume depletion and critical electrolyte imbalances, such as hyponatremia (low sodium) and hypokalemia (low potassium), are officially documented.

Emergency Response and Management

The potential for marked hypotension to lead to severe outcomes like shock or acute renal impairment necessitates urgent medical intervention.

  • Immediate Action Required: If a suspected overdose victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened, emergency services must be called immediately.
  • Antidote Status: No specific antidote is known for this overdose.
  • Official Management: Treatment is symptomatic and supportive, focusing on volume expansion for hypotension and correction of electrolyte imbalance. Official labeling also states that Losartan and its active metabolite are not effectively removed by hemodialysis.

Therapeutic Uses of Hyzart

What Hyzart Treats: Main Uses and Benefits

The primary therapeutic scope of Hyzart is commonly used to help with symptoms related to systemic imbalance by managing high blood pressure. This combination is relevant in chronic clinical settings.


The medication is commonly used for conditions characterized by periods of heightened symptoms such as essential hypertension. It is applied in clinical settings that involve acute or unstable symptom patterns where additional management of discomfort is required, rather than being limited to initial treatments. This supportive approach may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

In specific scenarios, the therapy is considered relevant in situations where patients experience Left Ventricular Hypertrophy (LVH) alongside hypertension. It is commonly used to help with addressing the need for reduction of symptoms associated with acute or episodic changes and contributes to easing the overall symptom load on the cardiovascular system.


Quick Fact: Support for Symptoms Linked to Organ-Specific Functional Stress This combination is used for managing the symptoms that create noticeable physiological strain, contributing to improved comfort during symptomatic periods.

Regulatory References

  1. U.S. National Library of Medicine DailyMed overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Hyzart — official regulatory information

Populations for whom use is allowed (as stated in label):

  • Adult Patients with Hypertension.
  • Adult Patients with Hypertension and Left Ventricular Hypertrophy.

Populations for whom use is contraindicated:

  • Patients with Hypersensitivity to Losartan, Hydrochlorothiazide, or any sulfonamide-derived drug.
  • Pregnant Women in the Second and Third Trimesters; the medicine must be discontinued as soon as pregnancy is detected.
  • Patients with Anuria (inability to produce urine).
  • Patients with Severe Hepatic Impairment or Severe Renal Impairment (Creatinine Clearance le 30 mL/min).
  • Diabetic Patients or those with impaired renal function receiving concomitant Aliskiren.

Age-related eligibility rules:

  • Pediatric Use (< 18 years): Not recommended; safety and efficacy have not been established.
  • Older Adult Use (> 65 years): Established; no geriatric-specific problems demonstrated.

Pregnancy and lactation eligibility status:

  • Pregnancy: Contraindicated in the 2nd and 3rd trimesters.
  • Lactation: Not Recommended.

Official eligibility statements: Regulatory labeling establishes absolute contraindications for patients with anuria or known hypersensitivity to components. Use is strictly contraindicated during later stages of pregnancy. Furthermore, eligibility is restricted for patients with severe organ dysfunction (liver or kidney). Use is not recommended for the pediatric population as safety data has not been established. The medicine is officially eligible for use in adult patients with hypertension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

Category/Medicine Interaction Concern
Aliskiren (in patients with diabetes) Increased risk of serious adverse events including hypotension, hyperkalemia, and renal failure (dual blockade of the Renin-Angiotensin System).

Clinically Significant Interactions

Category/Medicine Interaction Mechanism & Concern
Potassium-Increasing Agents (e.g., potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium) Increased risk of hyperkalemia (elevated serum potassium).
Lithium Reduced renal clearance of Lithium, leading to elevated serum Lithium levels and increased risk of toxicity. Monitoring is essential.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the antihypertensive and diuretic effects and increase the risk of renal function deterioration, particularly in elderly or volume-depleted patients.
Bile Acid Sequestrants (Cholestyramine, Colestipol) Reduce the gastrointestinal absorption of the hydrochlorothiazide component. Separation of dosing times is typically advised.

Other Interactions

  • Other Antihypertensive Agents (e.g., ACE inhibitors): Concomitant use with other agents blocking the RAS (except Aliskiren in restricted patients) requires close monitoring for hypotension, hyperkalemia, and changes in renal function.
  • Antidiabetic Drugs: Dosage adjustment of antidiabetic medication may be required as the thiazide component may alter glucose tolerance.

Mechanism of Action

How Hyzart Works

Hyzart modulates key physiological systems by exerting a combined action across two distinct pathways: the hormonal regulation of blood vessel tone and the renal regulation of fluid volume. This dual mechanism influences pressure-regulating systems simultaneously.

It contains a component that targets the Renin-Angiotensin-Aldosterone System (RAAS). This part acts as an antagonist to the Angiotensin II Type 1 ( AT1) receptors located on vascular smooth muscle. Blocking Angiotensin II binding causes the blood vessels to widen, which alters the resistance encountered by blood flow and modulates systemic vascular resistance.

The second component operates directly on the kidneys, functioning as an inhibitor of specific renal salt transporters responsible for reabsorbing sodium ( Na^+) and chloride ( Cl^-) from the kidney tubules. Preventing this reabsorption results in a greater excretion of salt and water, which decreases the total fluid volume circulating in the bloodstream, resulting in a change to systemic volume status.

These two mechanisms—modulating vascular tone and decreasing circulating volume—operate via independent pathways. The resulting combined effect is a lowering of the force and pressure within the arteries.

Dosage and Administration Information

Official Instructions for Use

Hyzart (losartan/hydrochlorothiazide) is an oral combination tablet and must be used strictly according to the official instructions for administration. The medicine is taken once daily.


Administration and Dosing Schedule

Procedural Element Official Instruction
Route and Frequency Taken orally once daily.
Timing with Meals The tablet can be taken with or without food.
Starting Dose The usual starting dose is 50 mg/12.5 mg once daily.
Dose Titration The dosage may be increased after 3 weeks of therapy to a maximum of 100 mg/25 mg once daily.
Preparation No preparation steps (e.g., dilution, shaking) are required. Swallow the tablet whole.

Rules for Missed Doses and Specific Populations

Missed Dose Rule: If a dose is missed, take it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed dose and take the next dose at the regular time. Do not take two doses at the same time.

Pediatric Use: Use in children and adolescents under 18 years of age is not recommended due to insufficient data on safety and efficacy.

These labeled instructions define the standardized approach to using the medicine, focusing solely on the correct method and frequency of administration and dosage limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hyzart

Evidence for Use in Essential Hypertension

Research has primarily focused on evaluating this combination medicine in adults with high blood pressure (essential hypertension). The main evidence comes from short-term, randomized controlled trials (RCTs), many of which were double-blind and placebo-controlled. These trials typically studied the medicine over defined time intervals, such as 4 to 12 weeks.

In these research settings, the primary outcomes monitored were changes in Sitting Systolic and Diastolic Blood Pressure (SBP and DBP) measurements taken at the doctor’s office. Studies report how symptoms evolved in the observed populations of patients receiving the combined agent compared to those receiving placebo or monotherapy. These findings describe patterns observed in the studies that measured the outcomes related to systemic or functional imbalance associated with hypertension.

Evidence for Stroke Risk Reduction in High-Risk Patients

Separate large-scale, long-term research was evaluated in a specific group of high-risk patients. This research examined patients with hypertension who also presented with Left Ventricular Hypertrophy (LVH), a condition reflecting physiological strain outcomes monitored. These studies examined the incidence of major events, with the primary focus on fatal and non-fatal stroke events.

The long-term study examined the incidence of stroke between two different treatment regimens in the high-risk population over a period of four years or more. This research describes how the incidence of major events was observed in studies focusing on conditions characterized by fluctuating or episodic manifestations.

What is Still Uncertain about Hyzart Research

While a significant amount of data exists regarding the effects on blood pressure, research is ongoing in several areas. Long-term effects are not fully established specifically for the fixed-dose combination structure across all possible patient profiles. The comparative evidence is lacking for certain scenarios, particularly comparing the fixed-dose combination to the separate use of the two ingredients in all populations.

Also, the evidence quality varies across studies for many of the secondary outcomes related to physical discomfort or metabolic shifts. The available data are still emerging for some less common hypertensive conditions or metabolic features, and therefore, certainty remains limited in these specialized areas.

Key Studies & References

  1. LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE tablet, film coated - DailyMed (FDA Labeling)
  2. Angiotensin Receptor Blockers and HCTZ Combination Drugs - StatPearls (NCBI/NIH)
  3. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect

Frequently Asked Questions (FAQ)

Common questions about Hyzart (FAQ)

Q: Is Hyzart considered a long-term treatment or just for short-term use?

A: Official information describes this medicine as a treatment for high blood pressure, which is typically a chronic condition. Therefore, Hyzart is used for the long-term management and control of blood pressure and is utilized for the long-term management of the condition.

Q: Does Hyzart have a generic name or version available in the market?

A: The two active ingredients in Hyzart are losartan potassium and hydrochlorothiazide. Both components are widely available as a generic combination. This combination is widely available as a generic formulation.

Q: Are there any specific foods that are described as interacting with Hyzart?

A: According to official product information, certain dietary elements should be managed while using this medicine. Official labeling describes a concern regarding the consumption of grapefruit or grapefruit juice, as it may alter the drug's levels in the blood. Patients are also noted as being advised against potassium-containing salt substitutes.

Q: Does Hyzart need to be taken at the exact same time every day to maintain its effect?

A: Official guidance emphasizes the need for consistent, once-daily use. This routine helps ensure the drug's activity persists effectively over the full 24-hour period, and this consistency supports the intended daily effectiveness.

Q: What does the official documentation say about what to do if the medicine causes stomach upset?

A: For mild gastrointestinal symptoms, such as nausea, official documentation notes that taking the tablets with or after a meal may be a helpful approach. If more severe issues like vomiting or diarrhea occur, official safety considerations include maintaining fluid intake.

Q: Does Hyzart require special monitoring or routine blood tests during use?

A: Official product labeling indicates that regular monitoring of key laboratory parameters is necessary during treatment. This typically includes blood tests to check kidney function, serum electrolytes, and potassium levels.

Q: Does Hyzart treat the symptoms of the condition or the underlying cause?

A: Hyzart works to control high blood pressure by helping the heart and arteries function properly and by increasing fluid excretion. The medicine is for the long-term management of high blood pressure, but official information indicates it does not cure the underlying condition itself.

Q: Is Hyzart a cure for the condition it treats?

A: No, Hyzart is classified as an antihypertensive agent used for the management and control of high blood pressure. Official regulatory documents indicate that the medicine helps to keep blood pressure low, but it does not provide a cure for the condition.

Q: What is the expected timeline for Hyzart to start showing an effect?

A: The initial blood pressure lowering effect from Hyzart can begin within 1 to 2 hours of taking a dose. However, the maximal therapeutic effect from the medicine requires consistent use and may take 3 to 6 weeks to fully develop.

Q: How long do the common side effects of Hyzart typically last?

A: Official documents report that common mild side effects, such as headaches and dizziness, usually lessen or go away after the first week of starting treatment.

Q: Are the reported side effects of Hyzart considered permanent?

A: Most reported adverse effects are temporary and typically stop upon discontinuation of the medicine. However, regulatory warnings note that the cumulative, long-term use of the diuretic component is described as associated with an increased risk of Non-Melanoma Skin Cancer.

Q: Can Hyzart affect a person’s ability to drive or operate heavy machinery?

A: Yes, because the medicine can cause side effects like dizziness, lightheadedness, or fainting. Official guidance states that individuals should not drive or operate heavy machinery until they understand how the medicine affects their personal alertness and coordination.

Q: Is it common for Hyzart to cause changes in weight?

A: Weight gain or weight loss was not commonly reported in the clinical trials for this medicine. Official documents note that rapid or unusual weight changes may warrant a safety evaluation.

Q: What official guidance exists regarding the use of alcohol while taking Hyzart?

A: Official documentation contains warnings regarding alcohol consumption, stating a concern that it may increase the risk of orthostatic hypotension, which is a significant drop in blood pressure when standing up.

Q: Does taking vitamins or dietary supplements interfere with Hyzart?

A: Yes, certain dietary supplements may interfere with how Hyzart works. Official information identifies supplements that contain potassium (like salt substitutes) or any herbs that have a known diuretic (fluid-removing) effect as potentially interfering.

Q: Can individuals with a history of heart issues use Hyzart safely?

A: Patients with a history of certain heart conditions, such as severe heart failure, may face a higher risk of kidney-related side effects. Official labeling indicates that close surveillance of kidney function is warranted for patients with certain pre-existing heart conditions.

Q: What is the meaning of the general warning about Hyzart and mental health changes?

A: Official reports indicate that psychiatric effects like insomnia, anxiety, confusion, and depression have been reported, although typically infrequently. Official documentation indicates that patients should inform their healthcare provider of any changes in mood or mental state.

Q: Is it possible for Hyzart to become less effective over a long period of use?

A: Pharmacokinetic studies describe the drug's metabolic action as remaining consistent and linear over time with repetitive dosing. This indicates a steady processing capability by the body and suggests no loss of effectiveness from drug metabolism over time.

Q: Is Hyzart described as habit-forming or physically addicting?

A: No, the medicine is not listed as a controlled substance by regulatory bodies such as the DEA. Hyzart is an antihypertensive agent and is therefore not classified as a drug of abuse.

Q: What is the primary way Hyzart is removed from the body?

A: The medicine is removed from the body through two primary pathways. The losartan component is mostly removed through biliary excretion, with a smaller amount through the urine. The hydrochlorothiazide component is largely eliminated unchanged by the kidneys.

Q: How quickly can Hyzart's effects wear off after stopping use?

A: Although the active components have a short half-life in the bloodstream, the therapeutic effects on blood pressure can persist for up to 1 to 2 weeks after treatment is abruptly stopped. Official documentation notes that this persistence of effect is a regulatory consideration when changes in therapy are implemented.

How should Hyzart be stored and disposed of?

How to Store and Dispose of Hyzart

Official Storage Requirements

Hyzart (losartan potassium and hydrochlorothiazide) must be stored at 25°C (77°F), classified as Controlled Room Temperature. Storage is permitted to temporarily range between 15°C and 30°C (59°F and 86°F), but the tablets must be protected from light and stored away from moisture.

To maintain product quality, the container must be kept tightly closed.

Safety and Disposal Mandates

Regulatory labeling mandates that Hyzart must be stored out of the reach of children. When discarding unused or expired medication, it is officially required not to throw away medicines via wastewater or household waste. Disposal should follow local regulations, often through a drug take-back program or by asking a pharmacist for proper instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hyzart found in:

A-Z Index: